Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Boehringer Ingelheim
Harvard Business School
Colorcon

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00311155 ↗ Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension Completed Sankyo Pharma Gmbh Phase 4 2006-03-01 This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
NCT00649389 ↗ Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension Completed Daiichi Sankyo Inc. Phase 3 2008-05-01 To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
NCT00649389 ↗ Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension Completed Daiichi Sankyo, Inc. Phase 3 2008-05-01 To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Condition Name

Condition Name for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Intervention Trials
Essential Hypertension 4
Hypertension 2
Healthy Subjects 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Intervention Trials
Hypertension 6
Essential Hypertension 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Trials by Country

Trials by Country for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Location Trials
United States 69
Germany 2
Netherlands 2
Belgium 2
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Location Trials
Illinois 2
Pennsylvania 2
Kansas 2
Kentucky 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Clinical Trial Phase Trials
Completed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Sponsor Name

Sponsor Name for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Sponsor Trials
Daiichi Sankyo Inc. 4
Daiichi Sankyo, Inc. 4
Torrent Pharmaceuticals Limited 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Sponsor Trials
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Merck
Colorcon
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.